Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis

Fig. 3

Differences in blood vessel density following different treatment regimens. a Formalin fixed liver sections with CRC liver metastases were stained with antibodies to CD34 (staining of endothelial cells). First column Scale bar = 200 μm. Second column depicts magnified inset regions of first column images. Scale bar = 50 μm. T = live tumor, NT = necrotic tumor. Second inset in the OXi4503 treatment indicates central tumor vessels recovering ahead of live tumor repopulation. Arrow in the Sunitinib treatment indicates intact central vessel surrounded with live tumor cells. Arrows in the combination treatment show liver damage. b Quantification of CD34 positive vessels. Data is expressed as mean value ± SEM, with n ≥ 5 for each group. Data was not normally distributed and non-parametric analysis was performed and statistical significance determined using Mann-Whitney U test. (OXi4503 vs control *P < 0.001, Sunitinib and combination vs control *P < 0.001 and Sunitinib vs combination # P = 0.001)

Back to article page